Week In Review: Innocare Strikes $937 Million Deal With Biogen For BTK Inhibitor
July 17, 2021 at 13:47 PM EDT
Beijing InnoCare out-licensed ex-China rights for its BTK inhibitor to Biogen in a $937.5 million deal. Biogen will pay $125 million upfront and up to $812.5 million in milestones, plus royalties.
